2024
Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).
Xu Y, Lim Y, Bordeaux J, Aasi S, Alam M, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Grekin R, Mark L, Nehal K, Nghiem P, Olino K, Patel T, Scott J, Shaha A, Srivastava D, Schmults C. Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 39536442, DOI: 10.6004/jnccn.2024.7037.Peer-Reviewed Original ResearchConceptsMargin assessmentCell carcinomaNCCN GuidelinesHigh-risk basal cell carcinomasCutaneous squamous cell carcinomaDeep margin assessmentMohs micrographic surgerySquamous cell carcinomaBasal cell carcinomaNonmelanoma skin cancerMicrographic surgeryDermatofibrosarcoma protuberansCure rateOptimal patient outcomesUninvolved tissueAccurate resectionSkin cancerPatient outcomesNCCNCarcinomaHistological visualizationMarginal surfacesTissueCCPDMAResection
2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 1181-1203. PMID: 37935106, DOI: 10.6004/jnccn.2023.0056.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBasal cell carcinomaNCCN Clinical Practice GuidelinesClinical practice guidelinesSkin cancerTreatment optionsPractice guidelinesBasal cell skin cancerPrevalent treatment optionPrevious medical therapyLimitation of functionBCC occurrenceMedical therapyRisk stratificationBCC developmentCell carcinomaCancerCommon formOncologyAnnual rateEstimated ratesGuidelinesKey playersSurgeryCarcinomaHigh frequencyEvaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability
Belzer A, Pach J, Mortlock R, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal J. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD International 2023, 11: 174-175. PMID: 37252181, PMCID: PMC10213716, DOI: 10.1016/j.jdin.2023.02.007.Peer-Reviewed Original Research
2020
Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical Notes